We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Mixed Results Eyed for Generics’ Attacks on Shire ADHD Franchise
Mixed Results Eyed for Generics’ Attacks on Shire ADHD Franchise
May 22, 2012
Wall Street analysts predict Actavis’ ANDA on attention-deficit hyperactivity disorder (ADHD) drug Intuniv won’t infringe Shire’s patents, and the generic-drug maker could launch as soon as October if it wins approval.